Ironwood Pharmaceuticals Stock Fundamentals
| IRWD Stock | USD 6.48 0.16 2.41% |
Ironwood Pharmaceuticals fundamentals help investors to digest information that contributes to Ironwood Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Ironwood Stock. The fundamental analysis module provides a way to measure Ironwood Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ironwood Pharmaceuticals stock.
At present, Ironwood Pharmaceuticals' Operating Income is projected to increase significantly based on the last few years of reporting. The current year's EBIT is expected to grow to about 219.5 M, whereas Interest Expense is forecasted to decline to about 19.9 M. Ironwood | Select Account or Indicator |
Ironwood Pharmaceuticals Company Profit Margin Analysis
Ironwood Pharmaceuticals' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Ironwood Pharmaceuticals Profit Margin | (2.54) % |
Most of Ironwood Pharmaceuticals' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ironwood Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Ironwood Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Ironwood Pharmaceuticals has a Profit Margin of -2.5441%. This is 77.31% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The profit margin for all United States stocks is 100.32% higher than that of the company.
Ironwood Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ironwood Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Ironwood Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ironwood Pharmaceuticals competition to find correlations between indicators driving Ironwood Pharmaceuticals's intrinsic value. More Info.Ironwood Pharmaceuticals is rated fourth overall in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies . At present, Ironwood Pharmaceuticals' Return On Equity is projected to slightly grow based on the last few years of reporting.Comparative valuation analysis is a catch-all model that can be used if you cannot value Ironwood Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Ironwood Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ironwood Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Ironwood Pharmaceuticals' Earnings Breakdown by Geography
Ironwood Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ironwood Pharmaceuticals' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ironwood Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ironwood Pharmaceuticals by comparing valuation metrics of similar companies.Ironwood Pharmaceuticals is currently under evaluation in profit margin category among related companies.
Ironwood Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ironwood Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ironwood Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Ironwood Fundamentals
| Return On Equity | -5.75 | ||||
| Return On Asset | 0.0939 | ||||
| Profit Margin | (2.54) % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 1.6 B | ||||
| Shares Outstanding | 158.96 M | ||||
| Shares Owned By Insiders | 1.73 % | ||||
| Shares Owned By Institutions | 98.27 % | ||||
| Number Of Shares Shorted | 20.08 M | ||||
| Price To Earning | 18.35 X | ||||
| Price To Book | 2.59 X | ||||
| Price To Sales | 2.79 X | ||||
| Revenue | 442.74 M | ||||
| Gross Profit | 366.33 M | ||||
| EBITDA | 210.61 M | ||||
| Net Income | (1 B) | ||||
| Cash And Equivalents | 504.36 M | ||||
| Cash Per Share | 3.29 X | ||||
| Total Debt | 715.54 M | ||||
| Debt To Equity | 0.78 % | ||||
| Current Ratio | 26.52 X | ||||
| Book Value Per Share | (2.08) X | ||||
| Cash Flow From Operations | 183.43 M | ||||
| Short Ratio | 7.82 X | ||||
| Earnings Per Share | (6.78) X | ||||
| Price To Earnings To Growth | (0.26) X | ||||
| Target Price | 16.33 | ||||
| Number Of Employees | 267 | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 1.03 B | ||||
| Total Asset | 471.07 M | ||||
| Retained Earnings | (1.7 B) | ||||
| Working Capital | (42.81 M) | ||||
| Current Asset | 500.2 M | ||||
| Current Liabilities | 76.47 M | ||||
| Net Asset | 471.07 M |
About Ironwood Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ironwood Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ironwood Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ironwood Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.1 M | 1.1 M | |
| Total Revenue | 442.7 M | 231.7 M | |
| Cost Of Revenue | 1.6 M | 1.5 M | |
| Stock Based Compensation To Revenue | 0.07 | 0.07 | |
| Sales General And Administrative To Revenue | 0.80 | 1.38 | |
| Research And Ddevelopement To Revenue | 0.22 | 0.21 | |
| Capex To Revenue | (0.0006) | (0.0006) | |
| Revenue Per Share | 2.85 | 1.58 | |
| Ebit Per Revenue | 0.47 | 0.50 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:Check out Ironwood Pharmaceuticals Piotroski F Score and Ironwood Pharmaceuticals Altman Z Score analysis. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Ironwood Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.69) | Earnings Share (6.78) | Revenue Per Share 2.647 | Quarterly Revenue Growth (0.28) | Return On Assets 0.0939 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.